The latest Investing Matters Podcast episode with multi-award-winning fund manager and international bestselling author Lee Freeman-Shor has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is today pleased to provide an operational update.
Development Pipeline Update
Cytolytix (CLX001)
The assessment of formulation options for CLX001 has progressed during Q1 2024, with the lead formulation now demonstrated to have activity against cancer cells. Testing is ongoing to assess the safety of the formulated product.
ValiRx is also pleased to announce that Cytolytix has been awarded a Knowledge Transfer Voucher ("KTV") grant in conjunction with the Open University. This initial grant is being used in a pilot study to assess the effectiveness of Cytolytix's cancer-specific lytic peptides in Neuroendocrine Prostate Cancer ("NEPC"). NEPC is a highly aggressive form of cancer with a typical survival rate of less than one year. Unfortunately, there are currently no available therapies for NEPC which shares similar characteristics with triple-negative breast cancer, such as hormone independence, and a high likelihood of metastasis. This research will assess CLX001 with and without the formulation to better understand the mechanism and to assess the breadth of activity of the product against an additional cancer type.
These assessments will assist in defining whether the lead formulation is appropriate for further development and progression into formal preclinical studies.
Evaluation Projects
During the first quarter of 2024, two new evaluation projects have been added, from Dundee University to study a series of molecules proposed with proposed pro-senescence activity and from Imperial College London to evaluate a series of dual kinase inhibitor candidates. The agreement with Dundee announced on 12 February 2024 also includes an over-arching agreement to assess and routinely evaluate further opportunities originating from the Dundee Drug Discovery Unit. Testing on both new programmes has commenced in Inaphaea BioLabs and at external partners.
The evaluation work continues on the projects from StingRay and the University of Barcelona, with the latter expected to conclude in Q2 2024. Due diligence is underway on additional potential pipeline projects.
We are pleased with the continued interest shown in the ValiRx approach to assessing innovative technology, which has resulted in broadening of the evaluation pipeline into some exciting new approaches for the treatment of cancer.
Clinical Stage Assets
VAL201 remains subject to the Letter of Intent ("LoI") with TheoremRx Inc. The Board maintains regular communication with the TheoremRx team to determine whether there is continuing progress to secure the necessary financing, which will enable the proposed merger with EUDA Health and the VAL201 sub-license to complete. The sub-license contains provisions for upfront and early-stage milestone payment and will release the payment for work already conducted under the previously announced service
Val 201 the gift that never gives!
I highlighted 3 ways to get this to double digits with further potential for other news such as the 401 conclusion.
I think the first one is a dead cert now with so many clients waiting. 11 at the advanced stage so hopefully lots of RNS's in the coming weeks for significant upside from here.
201 and CLX are either progressing well or ongoing but even with a 5050 shot you could be looking at 500% plus from here if either came good in the next few weeks/months.
Therefore I feel very bullish that the plan will work out well. Love the low risk strategy just need to get this sold to large clients and bring them in to get closer to fair value. We all win when one of many gets a deal.
With so much time left and revenue to come hopefully from different sources I think we can only look up from here. Keep going and we may get to 10p plus in the coming weeks.
I have held this share for some time and when it hit 3p intra day I was stunned. When it closed 4p I was gobsmacked. 👊 This is the beginning of a significant rerate. Tomorrow will open blue and remain blue. You can thank me later!
GLA ♥